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Fatty acid synthase (FASN) is the enzyme that synthesizes fatty acids de novo in human cells. Although 
FASN is generally expressed at low levels in most normal tissues, its expression is highly upregulated in 
many cancers. Consistent with this notion, inhibition of FASN activity has demonstrated potential to halt 
proliferation and induce cell death in vitro and to block tumor growth in vivo. Consequently, FASN is widely 
recognized as a valuable therapeutic target. In this report, we describe a variety of 1,4-quinones and 9,10- 
anthraquinones, including several natural compounds and some newly synthesized compounds, that potently 
inhibit the thioesterase (TE) domain of FASN. Inhibition of recombinant TE activity, inhibition of cellular 
FASN, and cytotoxicity in human prostate cancer cell lines and normal fibroblasts, is shown for the most 
potent inhibitors. Collectively, the data illustrate the novel inhibitory capacity of the 1,4-quinone and 9,10- 
anthraquinone pharmacophores against FASN.
Key words  fatty acid synthase; thioesterase; chemotherapy
Fatty acid synthase (FASN) is the enzyme that synthesizes 
fatty acids in mammalian cells. FASN is a multifunctional 
protein comprised of seven functional domains. Over expres-
sion of FASN is a common characteristic of most tumors, and 
FASN expression levels correlate with disease progression.1) 
Accordingly, FASN activity is essential for the survival of 
cancer cells and tumor growth. Because this enzyme is absent 
in most normal adult tissues, there may be an opportunity to 
achieve a high therapeutic index with FASN-directed thera-
peutics that may be devoid of side effects typically associated 
with conventional anti-cancer agents. The FDA-approved drug 
Orlistat inhibits the thioesterase (TE) domain of FASN and 
can kill cancer cells in cell culture and xenograft models.2) 
However, Orlistat suffers from poor solubility and systemic 
bioavailability, and thus is not suitable as a cancer therapeutic 
in the current formulation.
In an effort to identify novel discovery leads, a library of 
8800 compound library (Nanosyn, Inc., U.S.A.) was screened 
using the recombinant FASN-TE domain in an assay con-
taining 10 µM of each compound and 4-methylumbelliferyl 
heptanoate as the substrate.3,4) Among the compounds that 
inhibited FASN-TE was 2-bromo-3-methyl-1,4-benzoquinone 
(NS-4390, 1a) (Fig. 1). Interestingly, the 1,4-dione moiety is 
found in a wide range of bioactive molecules in the animal, 
fungal and plant kingdoms—the vitamin K family being a 
notable example.5,6) These compounds can modulate cellular 
redox pathways and exhibit a broad range of biological activi-
ties.7) Salient to this manuscript are recent investigations into 
the cytotoxic and anti-proliferative properties of compounds 
containing 1,4-benzoquinone (common name) moiety.8–13) To 
the best of our knowledge, inhibition of the TE domain of 
FASN has not been postulated as a mechanism for the ability 
of this class of compounds to inhibit tumor growth.
An analysis of naturally occurring, commercially available, 
and new synthetic 1,4-benzoquinones, 1,4-naphthoquinones, 
9,10-anthraquinones (Fig. 1, Chart 1) was performed to de-
velop structure–activity relationship (SAR) information for 
FASN-TE at an initial concentration of 10 µM. Included are the 
naturally occurring compounds menadione (1c), plumbagin 
(1d), lawsone (1e), juglone (1g), and naphthazarin (1i). The 
1,4-naphthoquinones (1a–i) and 1,4-benzoquinones (2a–g) 
(Table 1) display potent inhibition of FASN-TE, except for 
compound 1e. In contrast, the more complex naturally occur-
ring compounds (3–7) inhibit with less potency (Table 1). The 
1,4-quinones with known anti-cancer activity like mitomycin 
C, doxorubicin, geldanamycin, streptonigrin and mitoxantone 
did not inhibit; lapachol and β-lapachone exhibited weak inhi-
bition potency (data not shown). All of the 1,4-benzoquinones 
(2a–c, 2e–g) with the exception of 2d show complete inhibi-
tion (Table 1) of FASN-TE at 10 µM, but because of their high 
level of chemical reactivity were not assessed further with TE 
or in cellular assays.
The IC50 values against recombinant TE were determined 
for compounds 1a–i, 2e–g, and 3. The 1,4-naphthylquinones 
(1a–i) show a much wider SAR profile with the IC50 values 
ranging from 0.1 µM to greater than 100 µM. As expected, 
compounds 1b, 1f, and 1g had the lowest IC50 values of 
0.9 µM, 0.3 µM, and 0.1 µM, respectively, and compound 1e had 
the highest IC50 value of over 100 µM. Based on this dataset, 
we reasoned that the structure–activity is driven principally 
by substituent effects of moieties directly attached to the 
quinone ring. Overall activating groups (Electron Donating 
Groups, EDGs) diminish inhibition, while deactivating groups 
(Electron Withdrawing Groups, EWGs) have nominal to a 
positive effect on inhibition. Compound 1e containing a strong 
EDG consistent with the SAR has low inhibition capacity; 
likewise compound 4 with three weak EDGs is a nominal 
inhibitor. The natural products 6 and 7 that contain strong 
EDGs (methoxy and hydroxy) also show diminished ability to 
inhibit TE. Importantly, the best compounds are comparable 
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in potency to Orlistat and its congener Ebelactone B, with IC50 
values of 0.3 and 0.8 µM, respectively.
In an effort to test substituent effect hypotheses and to 
reduce overall chemical reactivity, several analogs were syn-
thesized: one compound with a strong EDG (1h) resulting 
from the treatment of juglone with morpholine and some with 
weak to very weak electron donating groups (EDGs; 2e–g). 
As shown in Chart 1, these compounds were synthesized by 
reaction of the quinone precursor with a sulfur or nitrogen nu-
cleophile leading to the substituted 1,4-dihydroxy compound 
(the reduced form of the quinone). Oxidation of the thiol in-
termediates was accomplished in high yield by dissolving the 
thiol substrates in methylene chloride and using an aqueous 
solution of sodium periodate and benzyltrimethylammonium 
bromide as a phase transfer catalyst13) to afford the desired 
product (2e–g). In contrast, the morpholino containing inter-
mediate auto-oxidized to provide the desired compound (1h).
Supporting our hypothesis, the thio compounds (2e–g) are 
potent inhibitors; while the morpholino compound (1h) was 
a nominal inhibitor. The improved inhibition of the former 
compounds is most likely due to their lack of aromatic rings 
around the 1,4-benzoquinone core structure, as the naph-
thoquinone 1h or the anthraquinone 5 do, and the missing 
electron cloud of the phenyl rings decreases the electron do-
Fig. 1. 1,4- and 9,10-Diones Tested against Recombinant FASN-TE and FASN
Chart 1
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nating capability of the 2-alkyl-substituted 1,4-benzoquinone 
derivatives. We surmise that Michael addition is one plausible 
mechanism for enzyme inhibition, though analogs with fully 
substituted quinone rings (1a, 5, 6, 7) still retain the ability to 
inhibit. Further work will be required to develop a mechanis-
tic basis for the observed SAR; for example, affinity measure-
ments (Ki) and determination of reversibility of inhibition will 
be critical in uncovering the physicochemical determinants of 
the observed inhibition data.
Inhibition of cellular FASN activity was performed for 
selected compounds in two prostate cancer cell lines (PC3 
and DU145) and in normal fibroblast (FS4) using an assay 
that measures the incorporation of the 14C-acetate precursor 
into lipids.14) Not surprisingly, likely owing to low solubility 
in solution and cellular availability, there is little correlation 
between the ability of a compound to inhibit recombinant TE 
and inhibition of cellular FASN activity (Pearson’s R=0.1). 
Interestingly, the compounds that best inhibited 14C-acetate in-
corporation are in the simple 1,4-naphthoquinone family (1a, 
1b, 1d, 1f, 1g, 1i). The most potent inhibitors of recombinant 
TE that showed no inhibition of endogenous enzyme are the 
2-thio-substituted 1,4-benzoquinones (2e–g). A high level of 
nonspecific chemical reactivity and/or a myriad other factors 
may be contributing to the observed contrast in SAR between 
these assays.
There is also a correlation between the ability of a quinone 
analog to inhibit cellular FASN and the potency (EC50) at kill-
ing tumor cells. The inhibition of 14C-acetate uptake and EC50 
for inhibition of PC3 cell growth is correlated with a Pearson’s 
r=0.85. Prostate cancer cells expressing the highest level of 
FASN (DU145) used in this study show an even higher cor-
relation, r=0.92. Despite this strong relationship, only a few 
of the compounds demonstrated a marginal therapeutic index 
which was calculated as the cell killing ratio of cancer and 
FS4 fibroblasts EC50 values (data not shown). Based on the 
8 µM EC50 value of Orlistat for PC-3 cells and negligible cy-
totoxicity to fibroblasts and normal epithelial cells; the com-
pounds studied herein clearly need significant optimization to 
move toward therapeutic use.2)
In summary, we have demonstrated that 1,4-benzoquinones 
and 1,4-naphthoquinones, as well as a number of natural 
products containing the 1,4-benzoquinone and the 9,10- 
anthraquinone moieties, inhibit the TE domain of FASN as 
well as cellular FASN activity. These compounds are not 
based on Orlistat structure, thus are expected to have differ-
ent pharmacological properties than Orlistat. Nonetheless, the 
ability of these compounds to inhibit human pancreatic lipase 
will need to be performed in the future. We surmise that the 
bioactivity of these compounds may in some cases contribute 
to the widely observed anti-cancer properties of 1,4-qui-
nones.7–12) Additionally, the SAR shown herein is a starting-
point for the rational design of therapeutics that target the TE 
domain of FASN that are distinct from Orlistat.
Experimental
General  All reagents and solvents were used as purchased 
without further purification. 1H-NMR spectra were recorded in 
the indicated solvent on a Bruker 300 MHz with tetramethyl-
silane (TMS) as internal standard (chemical shift in δ ppm). 
Mass [ES-MS (70 eV)] spectra were recorded on Agilent 1100 
LC/MSD spectrophotometer. Analytical TLC was performed 
on Silica Gel GHLF250 plates (Analtech) with visualization by 
UV (254 nm) chamber with protective filters. All compounds 
were purified by precipitation or by column chromatography 
Table 1. Effect of 1,4- and 9,10-Diones on FASN-TE, Fatty Acid Synthesis and Cell Killing
Cmpd
rTEa)  




Inhibition of  
FA synthesis  
IC50 (µM)
Cell killing EC50 (µM)
PC-3 FS4 PC-3 DU145
1a 78 12.5 10 9.4 11.8 19.2
1b 100 0.9 2.8 10.6 12.8 6.8
1c 54 21.9 —b) 16.7 48.4 —b)
1d 59 10.9 2.4 2.3 4.1 5.3
1e 10 >100 —b) >50 >100 —b)
1f 100 0.3 11.5 21 23.3 35.4
1g 100 0.1 6.8 6.3 5.8 10.6
1h 26 26.4 — —b) —b) —b)
1i 98 3.5 2.6 2.4 2.7 4.8
2a 100 —b) —b) —b) —b) —b)
2b 100 —b) —b) —b) —b) —b)
2c 100 —b) —b) —b) —b) —b)
2d 66 —b) —b) —b) —b) —b)
2e 99 6.4 >25 µM —b) —b) —b)
2f 96 6.2 >25 µM —b) —b) —b)
2g 100 0.2 >25 µM —b) —b) —b)
3 4 52.4 >25 µM 31.1 8.3 —b)
4 39 —b) —b) —b) —b) —b)
5 35 —b) —b) —b) —b) —b)
6 30 —b) —b) —b) —b) —b)
7 31 —b) —b) —b) —b) —b)
a) Recombinant TE domain of human FASN. b) Not determined.
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performed on silica gel (230–400 mesh, grade 60, Fisher).
Synthesis of 8-Hydroxy-2-morpholinonaphthalene-1,4-
dione (1h)  To a solution of juglone (30 mg, 0.172 mmol) in 
ethanol (1.4 mL) was added morpholine (17 µL, 0.172 mmol) 
at room temperature. A dark precipitate was observed. The 
sample was stirred at room temperature for 20 h, and then it 
was filtered (paper) and rinsed with cold ethanol (ca. 2 mL) 
and dried to give 34 mg (76% isolated yield) of 8-hydroxy-
2-morpholinonaphthalene-1,4-dione as a purple-brown solid. 
1H-NMR (DMSO-d6) δ: 7.655 (1H, t, J=0.028, 0.025 Hz), 
7.408 (1H, d, J=0.024 Hz), 7.199 (1H, d, J=0.028 Hz), 5.993 
(1H, s), 3.700–3.696 (4H, br s), 3.450–3.299 (4H, br s), 2.049 
(1H, s). LCMS m/z: 260 [{M+ 1}+].
General Procedure for the Synthesis of 2-Alkylthio-1,4-
benzoquinones (2e–g)  To a solution of 1.0 eq (2.11 mmol) 
of 1,4-benzoquinone in ethanol (9.2 mL) was added 1.0 eq 
(2.11 mmol) of thio-derivative at room temperature. The 
sample was stirred at room temperature for 1 h and monitored 
by thin layer chromatography until it was complete. Ethanol 
was removed by reduced pressure to obtain a solid (usually 
brown to orange in color) that was collected by filtration or 
purified by flash column chromatography with a hexane–ethyl 
acetate gradient. The resulting 2-alkylthiohydroxyquinone 
was dissolved in methylene chloride, placed in a separatory 
funnel and treated with an aqueous 0.467 M solution of 1.0 eq 
(2.11 mmol) of sodium periodate and a 0.022 eq (0.046 mmol) 
of benzyltrimethylammonium bromide (phase transfer re-
agent) and was shaken for 20 min in a Glas-Col Bench Top 
Shaker at room temperature. Reaction completion was identi-
fied by TLC. Upon completion, the heterogeneous mixture 
was washed with water (2×10 mL and brine (10 mL). The 
aqueous layers were back-extracted with methylene chloride 
(10 mL). The organic layers were combined, dried (Na2SO4), 
filtered (paper) and concentrated to dryness in vacuo to af-
ford the desired compounds as a solid. The resulting solid was 
purified by column chromatography, using hexanes and ethyl 
acetate gradient as mobile phase or by precipitation/recrystal-
lization from methylene chloride.
2-(Cyclopentylthio)cyclohexa-2,5-diene-1,4-dione (2e)  
Orange solid, yield 34%, 1H-NMR (CDCl3) δ: 6.832–6.714 
(2H, m), 6.491 (1H, d, J=0.008 Hz), 3.461–3.445 (1H, m), 
2.232–2.182 (2H, m), 1.860–1.714 (6H, m). LCMS m/z: 208 
[M+].
2-(Heptylthio)cyclohexa-2,5-diene-1,4-dione (2f)  Black 
solid, yield 22%, 1H-NMR (CDCl3) δ: 6.844–6.720 (2H, 
m), 6.408 (1H, d, J=0.007 Hz), 2.800 (2H, t, J=0.024 Hz), 
1.798–1.747 (2H, m), 1.499–1.472 (2H, m), 1.396–1.298 (6H, 
m), 0.932 (3H, t, J=0.022 Hz). LCMS m/z: 238 [M+].
2-(Phenylthio)cyclohexa-2,5-diene-1,4-dione (2g)  Or-
ange solid, yield 96%, 1H-NMR (CDCl3) δ: 7.523 (5H, bs), 
6.854 (1H, d, J=0.033 Hz), 6.706 (1H, dd, J=0.033 Hz, 
J=0.008 Hz), 5.918 (1H, d, J=0.008 Hz. LCMS m/z: 216 [M+].
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